| 15.705 -0.445 (-2.76%) | 07-02 15:58 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
GlycoMimetics, Inc. operates as a clinical-stage pharmaceutical company, specializing in the research and development of groundbreaking glycomimetic therapies. Its core mission is to address critical unmet medical requirements arising from various diseases within the United States. A key focus of their pipeline is uproleselan, an E-selectin inhibitor. This drug is being advanced for acute myeloid leukemia (AML), both as a combination therapy with chemotherapy and is currently undergoing a Phase 3 clinical trial for patients experiencing relapsed or refractory forms of AML. Additionally, the company is developing GMI-1359, a compound designed to target both E-selectin and a specific chemokine receptor. This candidate is aimed at treating cancers that affect the bone and bone marrow, encompassing a range of solid tumors. Beyond these lead programs, GlycoMimetics is also progressing other experimental treatments, such as GMI-1687, an E-selectin antagonist intended for the management of vaso-occlusive crises, and a series of galectin-3 antagonists, which are compounds that interact with carbohydrate-binding proteins. In terms of collaborations, GlycoMimetics maintains a cooperative research and development pact with the National Cancer Institute. The company has also entered into a licensing and collaboration deal with Apollomics (Hong Kong) Limited for the global advancement and commercialization of uproleselan and GMI-1687. Founded in 2003, GlycoMimetics, Inc. conducts its operations from its corporate headquarters in Rockville, Maryland.
Sat, 05 Sep 2026
GLYC stock reacts to reverse split and symbol change - ad-hoc-news.de
Thu, 13 Feb 2025
GlycoMimetics Inc. (GLYC) reports earnings - qz.com
Tue, 29 Oct 2024
GlycoMimetics Stock Triples To Become Top Gainer On Crescent Biopharma Merger Deal: Retail Goes Wild - Stocktwits
Tue, 29 Oct 2024
GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma - Business Wire
Thu, 25 Jul 2024
GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan - Business Wire
Mon, 24 Jun 2024
GlycoMimetics CMO Edwin Rock Buys 305,000 Shares - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|